New biologic stapokibart under safety review for stubborn sinus polyps
NCT ID NCT07483268
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing the safety of a new biologic drug called stapokibart in 600 adults with chronic sinusitis and nasal polyps (CRSwNP). Participants receive the drug as a shot under the skin. The main goal is to track any side effects or serious health events. This is an open-label study, meaning everyone knows they are getting the drug, and it focuses on safety rather than how well the drug works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Stapokibart (a biologic drug given as a shot under the skin)
- What this could lead to
- If this drug proves safe and effective, it could offer a new treatment option for people with chronic sinusitis and nasal polyps that is not controlled by other therapies.
- What could go wrong
- This is an early safety study, not designed to prove the drug works. Side effects may occur, and the drug may not help everyone. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRSWNP are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Tongren Hospital, CMU
Beijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.